The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2017

Filed:

Jun. 04, 2012
Applicants:

Young Woo Park, Daejeon, KR;

Ki Won JO, Daejeon, KR;

Chan Woong Park, Daejeon, KR;

Seok Ho Yoo, Daejeon, KR;

Myeoung Hee Jang, Daejeon, KR;

Hye Nan Kim, Daejeon, KR;

Seon Ha Yun, Daejeon, KR;

Kyu Won Cho, Daejeon, KR;

MI Ra Park, Daejeon, KR;

Inventors:

Young Woo Park, Daejeon, KR;

Ki Won Jo, Daejeon, KR;

Chan Woong Park, Daejeon, KR;

Seok Ho Yoo, Daejeon, KR;

Myeoung Hee Jang, Daejeon, KR;

Hye Nan Kim, Daejeon, KR;

Seon Ha Yun, Daejeon, KR;

Kyu Won Cho, Daejeon, KR;

Mi Ra Park, Daejeon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/622 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.


Find Patent Forward Citations

Loading…